{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:44:58Z","timestamp":1764791098297,"version":"3.46.0"},"reference-count":14,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>We implemented multiple nucleic acid amplification test platforms because of the limited availability of test kits for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the early stages of the pandemic. Interpretation of results generated by different platforms and prioritization for testing algorithms required cross-comparison.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To compare the analytical sensitivity of 3 commercial SARS-CoV-2 molecular assays, selected samples were studied in parallel with Cobas SARS-CoV-2 test, NxTAG CoV Extended Panel, and ID NOW COVID-19 assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>A total of 8043 SARS-CoV-2 tests performed from March 22 to April 19, 2020, were included in this study. For all 1794 positive specimens detected by the cobas SARS-CoV-2 assay, the cycle threshold (Ct) values were manually tracked and plotted to demonstrate the distribution of sample viral levels. Additionally, 50 and 63 low-positive specimens (Ct values &amp;gt;32) as well as 50 and 61 consecutive positive specimens by the cobas assay were tested with NxTAG and ID NOW, respectively, to estimate their relative sensitivities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>The Ct values of cobas SARS-CoV-2\u2013positive samples were evenly distributed throughout ranges of 13.32 to 39.50 (mean, 25.06) and 13.60 to 42.49 (mean, 26.45) for ORF1 and E gene targets, respectively. NxTAG reliably detected only specimens with E gene Ct values lower than 33, and is estimated to detect 89.4% of positive specimens detected by cobas assay. ID NOW had performance variation independent of Ct value and is estimated to detect 83.5% of cobas positives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Clinical specimens exhibit a wide range of viral burden, with a significant portion at low levels. Analytical sensitivity of testing platforms is critical for reliable detection of SARS-CoV-2 and uniform care to patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2020-0283-sa","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T15:16:07Z","timestamp":1594394167000},"page":"1303-1310","source":"Crossref","is-referenced-by-count":15,"title":["Commercial Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Molecular Assays: Superior Analytical Sensitivity of cobas SARS-CoV-2 Relative to NxTAG CoV Extended Panel and ID NOW COVID-19 Test"],"prefix":"10.5858","volume":"144","author":[{"given":"Run","family":"Jin","sequence":"first","affiliation":[{"name":"From the Molecular & Genomic Pathology Laboratory, Clinical Laboratories, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania (Jin, Hartnett)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Pettengill","sequence":"additional","affiliation":[{"name":"the Departments of Pathology, Anatomy, & Cell Biology (Pettengill, Peiper, Wang) and Surgery (Wang), Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole L.","family":"Hartnett","sequence":"additional","affiliation":[{"name":"From the Molecular & Genomic Pathology Laboratory, Clinical Laboratories, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania (Jin, Hartnett)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert E.","family":"Auerbach","sequence":"additional","affiliation":[{"name":"the Department of Pathology, Abington Memorial Hospital\/Abington-Jefferson Health, Philadelphia, Pennsylvania (Auerbach)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C.","family":"Peiper","sequence":"additional","affiliation":[{"name":"the Departments of Pathology, Anatomy, & Cell Biology (Pettengill, Peiper, Wang) and Surgery (Wang), Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixuan","family":"Wang","sequence":"additional","affiliation":[{"name":"the Departments of Pathology, Anatomy, & Cell Biology (Pettengill, Peiper, Wang) and Surgery (Wang), Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"2020102620020914500_i1543-2165-144-11-1303-b01","unstructured":"World Health Organization.\n\t\t\t\t\tNovel coronavirus (2019-nCoV) situation report 10.\n\t\t\t\t\thttps:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200130-sitrep-10-ncov.pdf.Published January 30,2020.\n\t\t\t\t\tAccessed May 4, 2020."},{"key":"2020102620020914500_i1543-2165-144-11-1303-b02","unstructured":"World Health Organization.\n\t\t\t\t\tCoronavirus disease 2019 (COVID-19) situation report 54.\n\t\t\t\t\thttps:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200314-sitrep-54-covid-19.pdf. Published March, 11 2020. Accessed May 4, 2020."},{"key":"2020102620020914500_i1543-2165-144-11-1303-b03","unstructured":"cobas SARS-CoV-2: qualitative assay for use on the cobas 6800\/8800 Systems\n          [package insert].\n          Pleasanton, CA:\n\t\t\t\t\tRoche Molecular Systems Inc;\n\t\t\t\t\t2020."},{"key":"2020102620020914500_i1543-2165-144-11-1303-b04","unstructured":"NxTAG CoV Extended Panel\n          [assay package insert].\n          Toronto, ON, Canada:\n\t\t\t\t\tLuminex Molecular Diagnostics Inc;\n\t\t\t\t\t2020."},{"key":"2020102620020914500_i1543-2165-144-11-1303-b05","unstructured":"ID NOW COVID19 [package insert].\n\t\t\t\t\tDes Plaines, IL:\n\t\t\t\t\tAbbott Molecular Inc;2020."},{"key":"2020102620020914500_i1543-2165-144-11-1303-b06","unstructured":"US Food & Drug Administration.\n\t\t\t\t\tCoronavirus (COVID-19) update: FDA informs public about possible accuracy concerns with Abbott ID NOW point-of-care test [news release].\n\t\t\t\t\thttps:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-informs-public-about-possible-accuracy-concerns-abbott-id-now-point. Published May 14, 2020. Accessed May 22, 2020."},{"key":"2020102620020914500_i1543-2165-144-11-1303-b07","doi-asserted-by":"crossref","unstructured":"Zhen\n              W,\n            \n            \n              Smith\n              E,\n            \n            \n              Manji\n              R,\n            \n            \n              Schron\n              D,\n            \n            \n              Berry\n              GJ.\n            \n          \n          Clinical evaluation of three sample-to-answer platforms for the detection of SARS-CoV-2\n           [published online\n          April\n          24,\n          2020].\n\t\t\t\t\tJ Clin Microbiol.doi:10.1128\/JCM.00783-20","DOI":"10.1128\/JCM.00783-20"},{"key":"2020102620020914500_i1543-2165-144-11-1303-b08","doi-asserted-by":"crossref","unstructured":"Rhoads\n              DD,\n            \n            \n              Cherian\n              SS,\n            \n            \n              Roman\n              K,\n            \n            \n              Stempak\n              LM,\n            \n            \n              Schmotzer\n              CL,\n            \n            \n              Sadri\n              N.\n            \n          \n          Comparison of Abbott ID NOW, Diasorin Simplexa, and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19\n          [published online\n          April\n          17,\n          2020].\n\t\t\t\t\tJ Clin Microbiol.doi:10.1128\/JCM.00760-20","DOI":"10.1128\/JCM.00760-20"},{"key":"2020102620020914500_i1543-2165-144-11-1303-b09","doi-asserted-by":"crossref","unstructured":"Harrington\n              A,\n            \n            \n              Cox\n              B,\n            \n            \n              Snowdon\n              J,\n            \n            et al.\n\t\t\t\t\t\n          Comparison of Abbott ID NOW and Abbott m2000 methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from symptomatic patients\n          [published online\n          April\n          23,\n          2020].\n\t\t\t\t\tJ Clin Microbiol.doi:10.1128\/JCM.00798-20","DOI":"10.1128\/JCM.00798-20"},{"key":"2020102620020914500_i1543-2165-144-11-1303-b10","doi-asserted-by":"crossref","unstructured":"Craney\n              AR,\n            \n            \n              Velu\n              P,\n            \n            \n              Satlin\n              MJ,\n            \n            et al.\n\t\t\t\t\t\n          Comparison of two high-throughput reverse transcription-polymerase chain reaction systems for the detection of severe acute respiratory syndrome coronavirus 2\n          [published online\n          May\n          7,\n          2020].\n\t\t\t\t\tJ Clin Microbiol.doi:10.1128\/JCM.00890-20","DOI":"10.1128\/JCM.00890-20"},{"key":"2020102620020914500_i1543-2165-144-11-1303-b11","doi-asserted-by":"crossref","unstructured":"Lieberman\n              JA,\n            \n            \n              Pepper\n              G,\n            \n            \n              Naccache\n              SN,\n            \n            \n              Huang\n              ML,\n            \n            \n              Jerome\n              KR,\n            \n            \n              Greninger\n              AL.\n            \n          \n          Comparison of commercially available and laboratory developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories\n          [published online\n          April\n          29,\n          2020].\n\t\t\t\t\tJ Clin Microbiol.doi:10.1128\/JCM.00821-20","DOI":"10.1128\/JCM.00821-20"},{"key":"2020102620020914500_i1543-2165-144-11-1303-b12","doi-asserted-by":"crossref","unstructured":"Uhteg\n              K,\n            \n            \n              Jarrett\n              J,\n            \n            \n              Richards\n              M,\n            \n            et al.\n\t\t\t\t\t\n          Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays\n          [published online\n          April\n          29,\n          2020].\n\t\t\t\t\tJ Clin Virol.doi:10.1016\/j.jcv.2020.104384","DOI":"10.1016\/j.jcv.2020.104384"},{"key":"2020102620020914500_i1543-2165-144-11-1303-b13","doi-asserted-by":"crossref","unstructured":"Kucharski\n              AJ,\n            \n            \n              Russell\n              TW,\n            \n            \n              Diamond\n              C,\n            \n            et al.\n\t\t\t\t\t\n          Early dynamics of transmission and control of COVID-19: a mathematical modelling study.\n\t\t\t\t\tLancet Infect Dis.\n\t\t\t\t\t2020;\n\t\t\t\t\t20(5):\n\t\t\t\t\t553\u2013\n\t\t\t\t\t558.\n\t\t\t\t\tdoi:10.1016\/S1473-3099(20)30144-4","DOI":"10.1016\/S1473-3099(20)30144-4"},{"key":"2020102620020914500_i1543-2165-144-11-1303-b14","doi-asserted-by":"crossref","unstructured":"Liu\n              Y,\n            \n            \n              Gayle\n              AA,\n            \n            \n              Wilder-Smith\n              A,\n            \n            \n              Rocklov\n              J.\n            \n          \n          The reproductive number of COVID-19 is higher compared to SARS coronavirus.\n\t\t\t\t\tJ Travel Med.2020;\n\t\t\t\t\t27(2):\n\t\t\t\t\ttaaa021.doi:10.1093\/jtm\/taaa021","DOI":"10.1093\/jtm\/taaa021"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/11\/1303\/2625774\/i1543-2165-144-11-1303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/11\/1303\/2625774\/i1543-2165-144-11-1303.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:36:13Z","timestamp":1764790573000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/144\/11\/article-p1303.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":14,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,7,10]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2020-0283-sa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"type":"electronic","value":"1543-2165"},{"type":"print","value":"0003-9985"}],"subject":[],"published":{"date-parts":[[2020,7,10]]}}}